ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "osteoporosis"

  • Abstract Number: 0111 • ACR Convergence 2020

    Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic

    Amanda Stefl1, Shikha Singla2, Jessica Michaud1, Kama Thomas2, Lisa Rein2 and Mary Ellen Csuka2, 1Froedtert Hospital, Milwaukee, WI, 2Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Glucocorticoids (GC) are used as a long-term treatment option for an estimated 1% of the US population. The American College of Rheumatology has maintained…
  • Abstract Number: 0130 • ACR Convergence 2020

    The Prevalence of Osteoporosis in Individuals with Osteoarthritis: A Systematic Review

    Timothy Varghese1, Ali Ahmadi Pirshahid2, Dongkeun Kim2 and Yueyang Li2, 1Schulich School of Medicine & Dentistry, Richmond Hill, ON, Canada, 2Schulich School of Medicine & Dentistry, London, ON, Canada

    Background/Purpose: There is controversy regarding the relationship between osteoarthritis (OA) and osteoporosis (OP). While OA may be associated with increased bone mineral density (BMD) due…
  • Abstract Number: 1588 • ACR Convergence 2020

    A Quality Improvement Project to Improve Bone Densitometry Ordering in Adult Patients on Chronic Glucocorticoids

    Katherine Kaufman1, Philip Chu1, Mithu Maheswaranathan1, Andrew Johannemann1, D Ryan Anderson1, Isaac Smith1, Akrithi Udupa1, Mary Buckley1, Laura Cannon1, Rachel Randell1 and David Leverenz1, 1Duke University, DURHAM, NC

    Background/Purpose: The 2017 ACR guideline for glucocorticoid-induced osteoporosis (GIOP) recommends DXA testing in patients aged ≥40 years on chronic glucocorticoids. We performed a quality improvement…
  • Abstract Number: 0112 • ACR Convergence 2020

    Description of Risk Factors at Baseline and Need of Bone Agent According to Hadji Recommendations in Patients Taking Aromatase Inhibitors as Breast Cancer Therapy

    David Montero-Seisdedos1, Oihane Ibarguengoitia-Barrena2, Lucía Vega-Álvarez2, Carmen Lucía García Gomez2, Itziar Calvo-Zorrilla3, Juan M. Blanco-Madrigal2, Maria Esther Ruiz-Lucea2, María Luz García-Vivar2, Eva Galindez-Agirregoikoa2, Ana R. Inchaurbe-Pellejero2, Olaia Fernandez-Berrizbeitia2, Clara E. Perez-Velasquez2, Eduardo Cuende-Quintana4, Amaia Bilbao-González3 and Iñaki Torre-Salaberri3, 1Basurto University Hospital, Bilbao, Pais Vasco, Spain, 2Basurto University Hospital, Bilbao, Spain, 3University Hospital of Basurto, Bilbao, Pais Vasco, Spain, 4Basurto University Hospital, Madrid, Spain

    Background/Purpose: A well-known adverse effect of aromatase inhibitors (AI) in the bone is the loss of mineral density with the consequent increased risk of fracture…
  • Abstract Number: 0131 • ACR Convergence 2020

    Analysis of the Total Body Composition in a Cohort of Patients with Elderly Onset Arthritis

    Anahy María Brandy García1, Melania Martinez-Morillo2, Agueda Prior3, Rosa Serrano1, Lourdes Mateo4, Monica Guma5 and Laia Gifre2, 1Hospital Germans Trias i Pujol, Badalona, Spain, 2Hospital Germans Trias i Pujol, Barcelona, Spain, 3Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, 4Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Badalona, 5University of California San Diego, La Jolla, CA

    Background/Purpose: Inflammatory arthritis in the elderly leads to greater comorbidity than that of the young patients, however, there are few data on body composition in…
  • Abstract Number: 1590 • ACR Convergence 2020

    Bone Health in ANCA – Associated Vasculitis Patients

    Deepa Ragesh Panikkath1, Sandy Lee2 and Christina Downey2, 1Loma Linda University Health, Department of Rheumatology, Loma Linda, CA, 2Loma Linda University Medical Center, Redlands, CA

    Background/Purpose: Glucocorticoids (GC) are an important mode of therapy in ANCA associated vasculitis (AAV), and osteoporosis (OP) and fractures are potential adverse effects seen. The…
  • Abstract Number: 0113 • ACR Convergence 2020

    Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines

    Marielys Figueroa Sierra1, Atefeh Vafa1, Shu Cao2, Yuanyuan Lu3, Helen Bateman4, John Carter1, Yih Chang Lin2, Raquel Cuchacovich1, Marcos Maldonado4, Joanne Valeriano-Marcet1 and Gabriela Montes-Rivera4, 1University of South Florida, Tampa, FL, 2University of South Florida, Morsani College of Medicine, Tampa, FL, 3Biostatistician at Graduate Medical Education Department, Tampa, FL, 4James A. Haley VA, Tampa, FL

    Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a potentially preventable complication in those who are maintained on glucocorticoid (GC) therapy.  It is imperative to identify these patients…
  • Abstract Number: 0132 • ACR Convergence 2020

    Prevalence of Osteoporosis and Fragitlity Fractures Is Not Different Between ACPA Positive Patients Compared to ACPA Negative Patients in a Real World Setting, Despite Longer Disease Duration and Glucocorticoid-Treatment

    Edgar Wiebe1, Desiree Freier1, Dörte Huscher2, Gloria Dallagiacoma3, Sandra Hermann1, Robert Biesen4, Gerd Burmester5 and Frank Buttgereit6, 1Charité University Medicine Berlin, Dep. of Rheumatology and Clinical Immunology, Berlin, Germany, 2Charité University Medicine Berlin, Dep. of Biometry and Clinical Epidemiology, Berlin, Germany, 3University of Verona, Dep. of Rheumatology, Verona, Italy, 4Charité University Medicine, Dep. of Rheumatology and Clinical Immunology, Berlin, 5Charité University Hospital Berlin, Berlin, Germany, 6Charité University Medicine, Berlin, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is associated with increased systemic bone loss, leading to a high risk for hip, vertebral and non-hip, non-vertebral fractures. Especially ACPA…
  • Abstract Number: 1591 • ACR Convergence 2020

    A Quality Improvement Project to Increase Vitamin D Prescribing for Pediatric Patients on Glucocorticoids

    Katherine Kaufman1, Mary Buckley1, Laura Cannon1, Rachel Randell1, Philip Chu1, Mithu Maheswaranathan1, Andrew Johannemann1, D Ryan Anderson1, Isaac Smith1, Akrithi Udupa1 and David Leverenz1, 1Duke University, DURHAM, NC

    Background/Purpose: Chronic glucocorticoid treatment in children increases the risk of bone loss, fractures, and reduced adult skeletal mass. The 2017 ACR Glucocorticoid-Induced Osteoporosis (GIOP) guidelines…
  • Abstract Number: 0114 • ACR Convergence 2020

    Incidence of Follow-Up Dual-Energy X-Ray Absorptiometry Scanner Error: A Contributor to Precision Error

    Kevin Lee1, Karam Al Jumaily1, Mu Lin2, Kerry Siminoski3 and Carrie Ye4, 1Internal Medicine, University of Alberta, Edmonton, AB, Canada, 2Alberta Health Services, Edmonton, AB, Canada, 3Radiology, University of Alberta, Edmonton, AB, Canada, 4Rheumatology, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Osteoporosis is characterized by decreased bone tissue microarchitecture. This leads to reduced bone density and quality and is a significant contributor to morbidity, mortality,…
  • Abstract Number: 0133 • ACR Convergence 2020

    Pharmacist-Driven Clinic Development for Patients with Incidental Vertebral or Hip Fractures

    Julie Ferm1, Lanh Dang1 and Gurjit Kaeley2, 1UF Health Jacksonville, Jacksonville, FL, 2University of Florida College of Medicine - Jacksonville, Jacksonville, FL

    Background/Purpose: Non-traumatic vertebral and hip fractures are detrimental complications of osteoporosis and those with a previous fracture have double the risk of subsequent fractures. The…
  • Abstract Number: 1973 • ACR Convergence 2020

    Treatment Sequences with Romosozumab Before or After Antiresorptive Medication

    Felicia Cosman1, David Kendler2, Bente Langdahl3, Benjamin Z Leder4, E Michael Lewiecki5, Akimitsu Miyauchi6, Maria Rojeski7, Michele McDermott7, Mary Oates7, Cassandra E Milmont8, Cesar Libanati9 and Serge Ferrari10, 1Columbia University, New York, NY, 2University of British Columbia, Vancouver, BC, Canada, 3Aarhus University Hospital, Aarhus, Denmark, 4Mass General Hospital, Harvard Medical School, Boston, MA, Boston, MA, 5New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 6Miyauchi Medical Center, Osaka, Japan, 7Amgen Inc., Thousand Oaks, CA, 8Amgen Inc., Thousand Oaks, 9UCB Pharma, Brussels, Belgium, 10Geneva University Hospital, Geneva, Switzerland

    Background/Purpose: Prior studies of anabolic/antiresorptive treatment sequences indicate that using teriparatide first followed by an antiresorptive results in greater bone mineral density (BMD) gains, particularly…
  • Abstract Number: 0115 • ACR Convergence 2020

    Improving Osteoporosis Screening in Men at a Resident-run Primary Care Clinic: A Quality Improvement Project

    Khiem Vu1, Chima Ohadugha1, Kevin Dao1, Rabih Nayfe2 and Andrew Mangano1, 1Grand Strand Medical Center, Myrtle Beach, SC, 2Carolina Health Specialists - Rheumatology, Myrtle Beach, SC

    Background/Purpose: There are known indications for osteoporosis screening in women. However, osteoporosis also occurs in men and fragility fractures are linked to increased morbidity and…
  • Abstract Number: 0188 • ACR Convergence 2020

    The Risk of Fractures in a Community-based Cohort of Patients with Rheumatoid Arthritis Compared with the Background Population

    Lisa Theander1, Jan Åke Nilsson2, Minna Willim3, Lennart T.H. Jacobsson4 and Carl Turesson5, 1Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Sweden, Malmö, Sweden, 2Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, 3Rheumatology, Department of Clinical Sciences, Lund, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, 4Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology and inflammation research, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, 5Rheumatology, Department of Clinical Sciences Malmö, Lund University, Department of Rheumatology, Skåne University Hospital, Malmö, Sweden., Malmö, Sweden

    Background/Purpose: Rheumatoid Arthritis (RA) has been associated with increased risk of osteoporosis and fractures. We have recently presented results on DXA measurements over 10 years…
  • Abstract Number: 1974 • ACR Convergence 2020

    Validation of a Deep Learning Based Algorithm to Diagnose Vertebral Compression Fractures

    John Page1, Franklin Moser2, Marcel Maya3, Ravi Prasad3 and Barry Pressman2, 1Amgen, Inc, Thousand Oaks, CA, 2Cedars-Sinai Medical Center, Los Angeles, CA, 3Cedars-Sinai Medical Center, Los Angeles

    Background/Purpose: Vertebral Compression Fractures are common in patients above age 50, but are often undiagnosed.  Patients with one VCF are at higher risk of other…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 23
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology